Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Neurology Gastroenterology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting Non-phase study NCT06280781

Imperial Prostate 9 – ATLAS (Approaches To Long-Term Active Surveillance)

Imperial Prostate 9 – ATLAS (Approaches To Long-Term Active Surveillance) — Recruiting • Non-phase study • Oncology • NCT06280781.

📅 30 Mar 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT06280781
Sponsor
Imperial College London
Start
2024-05-24
ClinicaliQ Trial Snapshot
  • Imperial Prostate 9 – ATLAS (Approaches To Long-Term Active Surveillance) — Recruiting • Non-phase study • Oncology • NCT06280781.
  • The goal of this intervention study is for patients on active surveillance for prostate cancer, to demonstrate that use of regular MRI scans is better able to detect cancer progression over 5 years compared to the current NICE defined strategy. Research Question….
  • Sponsor: Imperial College London.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The goal of this intervention study is for patients on active surveillance for prostate cancer, to demonstrate that use of regular MRI scans is better able to detect cancer progression over 5 years compared to the current NICE defined strategy. Research Question P - In patients who are on active surveillance for low to medium risk prostate cancer, I - is the use of regular MRI scans C - compared to current NICE defined standard of care, O - better at detecting cancer progression with less cost to the NHS…

Eligibility Snapshot
  • : * Age 18 years or above (no upper limit) * Patients with a prostate (either cis-male gender or trans-female gender with no prior androgen deprivation hormone use at all). * Diagnostic bi-parametric or multiparametric MRI * Diagnostic systematic biopsy +/- targeted biopsy * A histological diagnosis of localised prostate cancer * Patient chosen active surveillance

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Prostate Cancer: Diagnosis and Management (NICE NG131)
Oncology · 27 Mar 2026
Offer PSA testing to men aged 50–69 years after informed discussion of benefits and harms; consider testing men aged 40–49 with family…
View guideline →
Guideline
Bladder Cancer: Diagnosis and Management (NICE NG2)
Oncology · 27 Mar 2026
Blue light cystoscopy with hexaminolevinate improves detection of recurrent bladder tumours compared to white light cystoscopy alone, particularly for carcinoma in situ.…
View guideline →
Guideline
Head and Neck Cancers: Diagnosis and Management (NICE NG36)
Oncology · 27 Mar 2026
Refer urgently (two-week wait) any adult with unexplained persistent hoarseness, dysphagia, otalgia, oral ulceration lasting more than 3 weeks, or suspicious neck…
View guideline →
Guideline
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer (terminated appraisal)
Oncology · 17 Mar 2026
I appreciate your request, but I need to be transparent: the content provided only includes the title, metadata, and editorial notes -…
View guideline →
Guideline
Early Breast Cancer: Diagnosis and Management (NICE NG101)
Oncology · 25 Mar 2026
Perform triple assessment (clinical examination, imaging, and biopsy) for all suspicious breast lesions to confirm diagnosis before treatment planning Offer breast-conserving surgery…
View guideline →
Clinical Brief
NHS cancer jab could mean patients spend hours less in hospital
Oncology · BBC Health · 03 May 2026
Injectable immunotherapy formulation reduces administration time from hours to minutes, potentially decreasing hospital visits and improving patient experience Thousands of NHS cancer…
View brief →